Oruka Financial Statements From 2010 to 2026

ORKA Stock   26.55  1.26  4.53%   
Oruka Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Oruka Therapeutics' valuation are provided below:
Market Capitalization
1.3 B
We have found one hundred twenty available trending fundamental ratios for Oruka Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Oruka Therapeutics recent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 307.6 M. The current year's Enterprise Value is expected to grow to about 250.4 M

Oruka Therapeutics Total Revenue

56.58 Million

Check Oruka Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oruka Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 23.1 K, Interest Expense of 1.4 M or Total Revenue of 56.6 M, as well as many indicators such as Price To Sales Ratio of 2.28, Dividend Yield of 0.8 or PTB Ratio of 0.73. Oruka financial statements analysis is a perfect complement when working with Oruka Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Oruka Stock
Check out the analysis of Oruka Therapeutics Correlation against competitors.
For information on how to trade Oruka Stock refer to our How to Trade Oruka Stock guide.

Oruka Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets478.2 M455.4 M103.5 M
Slightly volatile
Short and Long Term Debt Total827.6 K871.2 K974.2 K
Slightly volatile
Other Current Liabilities8.9 M8.4 M3.8 M
Very volatile
Total Current LiabilitiesM11.7 M5.1 M
Pretty Stable
Total Stockholder Equity461.5 M439.6 M96.4 M
Slightly volatile
Property Plant And Equipment Net1.7 M934.2 K1.2 M
Slightly volatile
Accounts Payable3.3 M3.1 M1.5 M
Slightly volatile
Cash74.4 M70.8 M31.6 M
Slightly volatile
Non Current Assets Total18.1 M17.2 M4.9 M
Slightly volatile
Non Currrent Assets Other36.8 K38.7 K305.7 K
Slightly volatile
Cash And Short Term Investments453.6 M432 M96.6 M
Slightly volatile
Net Receivables502.7 K529.2 K615.9 K
Slightly volatile
Good Will3.7 M4.2 M4.6 M
Slightly volatile
Common Stock Shares Outstanding20.3 M19.3 M6.1 M
Slightly volatile
Short Term Investments379.2 M361.2 M179.8 M
Slightly volatile
Liabilities And Stockholders Equity478.2 M455.4 M103.5 M
Slightly volatile
Non Current Liabilities Total645.5 K679.5 K1.1 M
Slightly volatile
Other Current Assets1.2 M1.1 M1.3 M
Slightly volatile
Other Stockholder Equity437.6 M416.7 M212.7 M
Slightly volatile
Total Liabilities11 M12.4 M6.5 M
Pretty Stable
Total Current Assets455.1 M433.4 M98 M
Slightly volatile
Short Term Debt182.1 K191.7 K554.2 K
Slightly volatile
Common Stock35 K33.3 K17.6 K
Pretty Stable
Current Deferred Revenue19.6 K14.4 K18.1 K
Slightly volatile
Capital Lease Obligations774.4 K871.2 K950.9 K
Slightly volatile
Net Invested Capital303.4 M341.4 M372.6 M
Slightly volatile
Long Term Investments14.5 M16.3 M17.8 M
Slightly volatile
Property Plant And Equipment Gross830.4 K934.2 KM
Slightly volatile
Capital Stock2.4 M2.7 M2.9 M
Slightly volatile
Net Working Capital291.1 M327.4 M357.4 M
Slightly volatile

Oruka Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization23.1 K24.3 K236.2 K
Slightly volatile
Interest Expense1.4 M1.3 M567.7 K
Slightly volatile
Total Revenue56.6 M53.9 M45.1 M
Slightly volatile
Other Operating Expenses83.3 M79.3 M27 M
Slightly volatile
Cost Of Revenue23.1 K24.3 K3.6 M
Slightly volatile
Total Operating Expenses83.3 M79.3 M23.4 M
Slightly volatile
Research Development70.9 M67.6 M22.2 M
Slightly volatile

Oruka Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Change To Inventory288 K324 K353.6 K
Slightly volatile
Depreciation23.1 K24.3 K231.3 K
Slightly volatile
Total Cash From Financing Activities542.8 M517 M155.8 M
Slightly volatile
End Period Cash Flow74.4 M70.8 M33 M
Slightly volatile
Begin Period Cash Flow24.7 M43 M23.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.282.438.1235
Slightly volatile
Dividend Yield0.80.90.9808
Slightly volatile
PTB Ratio0.730.772.8662
Pretty Stable
Days Sales Outstanding5.05.2751.9263
Slightly volatile
Book Value Per Share21.5120.4915.5 K
Slightly volatile
Capex To Depreciation0.01920.02020.425
Slightly volatile
PB Ratio0.730.772.8662
Pretty Stable
EV To Sales1.531.6134.6967
Slightly volatile
Payables Turnover0.00850.0091.4506
Slightly volatile
Research And Ddevelopement To Revenue0.991.052.2217
Slightly volatile
Capex To Revenue0.00890.00940.2852
Slightly volatile
Cash Per Share24.4425.7319 K
Slightly volatile
Days Payables Outstanding44.2 K42.1 K14.2 K
Slightly volatile
Income Quality1.360.790.9344
Very volatile
Intangibles To Total Assets0.03940.04450.0394
Very volatile
Net Debt To EBITDA0.630.662.0108
Pretty Stable
Current Ratio27.3126.018.251
Slightly volatile
Tangible Book Value Per Share21.5120.4914.2 K
Slightly volatile
Receivables Turnover75.3171.7374.3076
Slightly volatile
Shareholders Equity Per Share21.5120.4915.5 K
Slightly volatile
Debt To Equity0.00240.00230.0168
Slightly volatile
Capex Per Share0.01230.0129666
Slightly volatile
Graham Net Net20.3719.45.9 K
Slightly volatile
Revenue Per Share150.7 K143.5 K148.7 K
Slightly volatile
Interest Debt Per Share0.160.173.4 K
Slightly volatile
Debt To Assets0.00270.00280.0106
Slightly volatile
Operating Cycle5.05.2751.9263
Slightly volatile
Price Book Value Ratio0.730.772.8662
Pretty Stable
Days Of Payables Outstanding44.2 K42.1 K14.2 K
Slightly volatile
Ebt Per Ebit0.740.860.937
Slightly volatile
Effective Tax Rate0.0010.00110.0155
Slightly volatile
Company Equity Multiplier1.211.191.1525
Slightly volatile
Long Term Debt To Capitalization0.110.190.1979
Very volatile
Total Debt To Capitalization0.00280.00290.0146
Slightly volatile
Debt Equity Ratio0.00240.00230.0168
Slightly volatile
Quick Ratio27.3126.018.251
Slightly volatile
Net Income Per E B T0.760.90.9647
Pretty Stable
Cash Ratio4.044.2513.5129
Pretty Stable
Days Of Sales Outstanding5.05.2751.9263
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0197
Slightly volatile
Price To Book Ratio0.730.772.8662
Pretty Stable
Fixed Asset Turnover4.974.744.9065
Slightly volatile
Debt Ratio0.00270.00280.0106
Slightly volatile
Price Sales Ratio2.282.438.1235
Slightly volatile
Asset Turnover0.370.350.3624
Slightly volatile
Price Fair Value0.730.772.8662
Pretty Stable

Oruka Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap307.6 M293 M157.4 M
Slightly volatile

Oruka Fundamental Market Drivers

About Oruka Therapeutics Financial Statements

Oruka Therapeutics stakeholders use historical fundamental indicators, such as Oruka Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Oruka Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Oruka Therapeutics' assets and liabilities are reflected in the revenues and expenses on Oruka Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Oruka Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue14.4 K19.6 K
Total Revenue53.9 M56.6 M
Cost Of Revenue24.3 K23.1 K
Research And Ddevelopement To Revenue 1.05  0.99 
Capex To Revenue 0.01  0.01 
Revenue Per Share143.5 K150.7 K
Ebit Per Revenue(0.32)(0.33)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Oruka Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oruka Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oruka Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oruka Therapeutics Stock:
Check out the analysis of Oruka Therapeutics Correlation against competitors.
For information on how to trade Oruka Stock refer to our How to Trade Oruka Stock guide.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oruka Therapeutics. If investors know Oruka will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oruka Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Oruka Therapeutics is measured differently than its book value, which is the value of Oruka that is recorded on the company's balance sheet. Investors also form their own opinion of Oruka Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Oruka Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oruka Therapeutics' market value can be influenced by many factors that don't directly affect Oruka Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oruka Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oruka Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oruka Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.